Ertugliflozin

BreastfeedingPediatric

FDA APPROVAL DATE: 12/19/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
Not recommended during the second and third trimesters of pregnancy

Contra-indicated in patients with severe renal impairment, end stage renal disease, or on dialysis.

Our database has 13 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
OTHER


Page last updated 06/08/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric